ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of Very Small Pediatric Donor Kidneys Utilizing Belatacept-Based Immunosuppression in Adult Recipients

K. Heinen1, A. Carlson2, A. Chan1, M. M. Eiting1, T. Larson1, B. Sirandas1, C. Truax1, L. Smith1

1University of Utah Health, Salt Lake City, UT, 2Medical University of South Carolina, Johnston, SC

Meeting: 2022 American Transplant Congress

Abstract number: 1697

Keywords: Donors, marginal, Efficacy, Immunosuppression, Kidney transplantation

Topic: Clinical Science » Kidney » 38 - Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Information

Session Name: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Abstract

Date: Tuesday, June 7, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Due to the lack of data utilizing belatacept as primary immunosuppression for adult recipients of very small pediatric donor kidneys, this study seeks to evaluate 1 year post-transplant outcomes of belatacept versus tacrolimus in this population.

*Methods: This retrospective, descriptive study assessed outcomes of adult transplant recipients utilizing very small pediatric donor kidney (defined as kidney size <6 cm, body weight <15 kg, or <3 years old) from 1/1/2018-1/1/2021. Primary outcomes compared patient survival, graft survival, and serum creatinine at 6 and 12 months post-transplant in patients on belatacept versus tacrolimus maintenance immunosuppression. Secondary outcomes assessed rates of acute rejection, de novo donor specific antibodies (DSA), infection, and graft thrombosis between the groups at 1 year.

*Results: Of the 24 patients identified, 1 patient experienced immediate graft thrombosis leading to graft loss and was excluded as the patient did not start therapy with either belatacept or tacrolimus. Thus, 23 recipients were included with 65% receiving belatacept. Other baseline characteristics seen in Table 1. Overall, 1 year post-transplant patient survival was 100% and graft survival was 91.3%. No difference was seen in patient survival, graft survival, serum creatinine, CMV or BK viremia requiring treatment, or bacterial infections between comparison groups (see Table 2). Besides the excluded patient, two other patients had graft thrombosis within 1 week of transplant which required intervention. One dual transplant on belatacept was salvaged with a single nephrectomy, and 1 en bloc transplant on tacrolimus required a complete nephrectomy. In the tacrolimus group, 1 patient developed acute cellular rejection and 1 developed a de novo DSA compared to no rejection or de novo DSA in the belatacept group.

*Conclusions: Belatacept appears to be an appropriate alternative maintenance agent to tacrolimus for adult recipients of very small pediatric kidneys with comparable rates of patient survival, graft survival, serum creatinine, acute rejection, and infection rates at 1 year post-transplant when compared to tacrolimus. Early graft thrombosis remains a concerning risk in this population and warrants further investigation.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Heinen K, Carlson A, Chan A, Eiting MM, Larson T, Sirandas B, Truax C, Smith L. Outcomes of Very Small Pediatric Donor Kidneys Utilizing Belatacept-Based Immunosuppression in Adult Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-very-small-pediatric-donor-kidneys-utilizing-belatacept-based-immunosuppression-in-adult-recipients/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences